Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kestead XT is a renal nutrition supplement developed by Steadfast Medishield for the conservative management of chronic kidney disease (CKD) stages II, III, and IV. It is a combination product containing alpha-ketoanalogues of essential amino acids and specific essential amino acids. The supplement is designed to be used in conjunction with a protein-restricted diet to help reduce the accumulation of nitrogenous waste products. Its mechanism of action involves the transamination of nitrogen from non-essential amino acids to the ketoanalogues, converting them into their corresponding essential amino acids. This process effectively recycles nitrogen, thereby reducing the urea load on the kidneys, alleviating uremic symptoms, and helping to preserve residual renal function while maintaining the patient's nutritional status during the pre-dialysis period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kestead XT.